# HISHOH Biopharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hishoh-biopharma

- Industry: Pharmaceuticals
- Headquarters: Tokyo, Japan
- Website: www.hishoh.jp/
- Total disclosed funding: $2.3M
- Latest round: Seed (Aug 4, 2021)
- Investors on record: 3

## About

Based in Tokyo, Japan, established in 2021, HISHOH Biopharma has been working with Daiichi Sankyo Co., Ltd. for sublingual immunotherapy for allergic diseases (allergen immunotherapy). In August 2021, HISHOH Biopharma raised JPY 250 million in seed funding from BioLite Japan, DBJ Capital, Mitsubishi UFJ Capital.

The firm focuses on enhancing sublingual immunotherapy for allergic diseases. Their proprietary compounds are designed to work synergistically with existing therapies, aiming to improve efficacy through a new mechanism of action.

## Funding rounds

- Seed, Aug 4, 2021, $2.3M — Mitsubishi UFJ Capital, DBJ Capital, BioLite Japan K.K.

## Investors

- Mitsubishi UFJ Capital (https://capitalatlas.ai/funds/mitsubishi-ufj-capital) — Seed
- DBJ Capital (https://capitalatlas.ai/funds/dbj-capital) — Seed
- BioLite Japan K.K. — Seed